Skip Nav Destination
Close Modal
Search Results for
drug
Update search
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-20 of 1549 Search Results for
drug
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Sort by
Journal Article
J Health Polit Policy Law (1979) 4 (1): 87–108.
Published: 01 February 1979
...James Christopher Anthony The Controlled Substances Act (CSA) is the prevailing “drug abuse” control statute in the United States. Its manifest objective is to prevent or reduce drug use's “substantial and detrimental effect on the health and general welfare of the American people.” Evaluating...
Journal Article
J Health Polit Policy Law (2013) 38 (3): 545–571.
Published: 01 June 2013
... and efficacy information that the provinces use comes from the federal government. We interviewed drug plan officials from eight of the ten provinces and two of three territories regarding their views on the Canadian drug safety system. Here we report on the following categories: the federal drug approval...
Journal Article
J Health Polit Policy Law (1998) 23 (2): 265–290.
Published: 01 April 1998
...Mae Thamer; Niall Brennan; Rafael Semansky Six countries—Canada, France, Japan, Sweden, the United Kingdom, and the United States—were studied to compare public policies affecting the development and marketing of pharmaceuticals for rare diseases (i.e., orphan drugs). Information was obtained from...
Image
in Treatment versus Punishment: Understanding Racial Inequalities in Drug Policy
> Journal of Health Politics, Policy and Law
Published: 01 April 2020
Figure 1 Yearly drug-related death rates (per 1,000 people). Notes : Total drug-related deaths per year from all illegal drugs and from opioids, methamphetamines, and cocaine. Calculated with data from the National Center for Health Statistics (see the online-only appendix for coding details).
More
Image
in Treatment versus Punishment: Understanding Racial Inequalities in Drug Policy
> Journal of Health Politics, Policy and Law
Published: 01 April 2020
Figure 3 Marginal effects of drug deaths on treatment sponsorship by drug type/race of victim: (a) all drugs; (b) opioids; (c) cocaine; (d) methamphetamine; (e) white victims; (f) black victims. Notes : Marginal effects of drug deaths on sponsorship of one or more bills related to treatment
More
Image
in Treatment versus Punishment: Understanding Racial Inequalities in Drug Policy
> Journal of Health Politics, Policy and Law
Published: 01 April 2020
Figure 3 Marginal effects of drug deaths on treatment sponsorship by drug type/race of victim: (a) all drugs; (b) opioids; (c) cocaine; (d) methamphetamine; (e) white victims; (f) black victims. Notes : Marginal effects of drug deaths on sponsorship of one or more bills related to treatment
More
Image
in Treatment versus Punishment: Understanding Racial Inequalities in Drug Policy
> Journal of Health Politics, Policy and Law
Published: 01 April 2020
Figure 3 Marginal effects of drug deaths on treatment sponsorship by drug type/race of victim: (a) all drugs; (b) opioids; (c) cocaine; (d) methamphetamine; (e) white victims; (f) black victims. Notes : Marginal effects of drug deaths on sponsorship of one or more bills related to treatment
More
Journal Article
Alene Kennedy-Hendricks, Erika Franklin Fowler, Sachini Bandara, Laura M. Baum, Sarah E. Gollust ...
J Health Polit Policy Law (2021) 46 (3): 381–407.
Published: 01 June 2021
...Alene Kennedy-Hendricks; Erika Franklin Fowler; Sachini Bandara; Laura M. Baum; Sarah E. Gollust; Jeff Niederdeppe; Colleen L. Barry Abstract Context: Understanding the role of drug-related issues in political campaign advertising can provide insight on the salience of this issue and the priorities...
FIGURES
| View All (4)
Journal Article
J Health Polit Policy Law (1979) 4 (2): 155–175.
Published: 01 April 1979
...Michael Ira Smith; Albert I. Wertheimer In 1973 the federal government moved to limit drug reimbursement to providers in federally sponsored or supported programs, to the lowest cost at which the drug is generally and consistently available unless a difference in therapeutic effect can...
Journal Article
J Health Polit Policy Law (1982) 7 (2): 521–523.
Published: 01 April 1982
...Peter Temin Milton Silverman, Philip R. Lee, and Mia Lydecker, Pills and the Public Purse: The Routes to National Drug Insurance (Berkeley: University of California Press, 1981), 232 pp., $15.95 hardbound Copyright © 1982 by the Department of Health Administration, Duke University Press...
Journal Article
J Health Polit Policy Law (2010) 35 (6): 961–997.
Published: 01 December 2010
...Thomas Rice; Janet Cummings The Medicare prescription drug benefit relies on private insurers. In most states, there are nearly fifty competing insurance plans available. The sheer number of choices makes it extremely difficult for Medicare beneficiaries, many of whom must cope with declining...
Journal Article
J Health Polit Policy Law (2013) 38 (3): 573–597.
Published: 01 June 2013
... contribute to economic efficiency by creating transparency as the foundation of competitive generic drug markets, reducing transaction costs, and favoring trade. The law in most countries requires manufacturers to designate pharmaceuticals with INNs in labeling and advertising. Generic substitution is also...
Journal Article
J Health Polit Policy Law (1994) 19 (4): 922–924.
Published: 01 August 1994
...Kenneth I. Kaitin Milton Silverman, Mia Lydecker, and Philip R. Lee. Bad Medicine: The Prescription Drug Industry in the Third World . Stanford, CA: Stanford University Press, 1992. 358 pp. $29.95 cloth. Copyright © 1994 by Duke University Press 1994 922 Journal of Health Politics...
Journal Article
J Health Polit Policy Law (2000) 25 (3): 595–597.
Published: 01 June 2000
...Drew Humphries Laura E. Gomez. Misconceiving Mothers: Legislators, Prosecutors, and the Politics of Prenatal Drug Exposure . Philadelphia: Temple University Press, 1997. 256 pp. $59.95 cloth; $19.95 paper. © 2000 by Duke University Press 2000 JHPPL 25.3-05.BkRevs (565-612) 5/12/00 11...
Journal Article
J Health Polit Policy Law (2000) 25 (4): 653–688.
Published: 01 August 2000
...William J. Moore; Karen Gutermuth; Etienne E. Pracht Aggregate pooled cross-sectional and time-series annual state data for 1985 to 1992 were used to estimate the systemwide effects of retrospective drug utilization review programs (Retro-DUR) on Medicaid drug and nondrug outcomes. The results...
Journal Article
J Health Polit Policy Law (2021) 46 (4): 599–609.
Published: 01 August 2021
.... Among these competing priorities is the issue of access to and affordability of prescription drugs. Here, the authors outline Biden's plan for directly lowering prescription drug spending for payers and patients and for expanding access to prescription medications through improved health insurance...
Journal Article
J Health Polit Policy Law (2021) 46 (6): 1053–1068.
Published: 01 December 2021
...Rachel E. Sachs Abstract Throughout his four years in office, President Trump made prescription drug pricing a focus of his policy agenda. President Trump not only used strong language to criticize the pharmaceutical industry and its practices but also introduced ambitious reform policies that had...
Journal Article
J Health Polit Policy Law (2022) 47 (4): 523–526.
Published: 01 August 2022
... of it, is hard to justify as necessary to encourage useful innovation (27, 52–53, 68). As she points out, compromises made to enact legislation often provide much bigger loopholes than might have been expected (69–70). For example, provisions for higher prices for “orphan” drugs have been manipulated in all...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 779–796.
Published: 01 December 2022
... on market prices. The authors review the application of IRP to cap the prices of negotiated outcomes in the context of US proposals for changing the way prescription drug prices are established for the Medicare program. They examine the economic, political, and administrative issues associated with the use...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 621–628.
Published: 01 December 2022
... prescription drug costs and access. The issue explores a broad set of topics that encompass drug approval processes, patent reform, efforts to reduce or eliminate out-of-pocket costs for high-value drugs, state and federal efforts to improve access to and reduce spending on prescription drugs, regulation...
1